J&J discontinues pivotal depression drug trial

The latest stories trending on MedCity News.

Editor's Pick

Top Story Johnson & Johnson Discontinues Pivotal Depression Drug Trial Due to Lack of Efficacy J&J said aticaprant showed insufficient efficacy in a Phase 3 test in major depressive disorder. The disappointing result follows the Phase 3 failure of a Neumora Therapeutics drug that addresses the same central nervous system target. Sponsored How Hidden Costs Can Undermine Your Healthcare Practice Presented by Elation Health MedCity News Sign up for this on-demand presentation, and learn the key areas where practices are losing time and money and provide actionable solutions to overcome them. Discover how embracing technology and strategic practice models can reduce fragmentation, combat burnout, and address payment limitations—empowering your practice to thrive in the year ahead. Register Here.

Featured News

This Hospital Exec Wants Nurses to Join the Ambient Listening Party Too Lavonia Thomas, nursing informatics officer at MD Anderson Cancer Center, hopes that nurses will gain more access to ambient listening tools that listen in on patient conversations and then generate summaries for documentation purposes. These AI tools have become popular among physicians in the past couple years. How Can EHRs Support the Shift to Value-Based Care and Reduce Clinician Burnout? [Sponsored] MedCity News Editor in Chief Arundhati Parmar moderated a webinar with Elation Health executives Dr Sara Pastoor, head of primary care advancement, and Meaghan Sullivan, senior sales engineer. GEM HEALTH Secures $7M to Advance Virtual Sleep Care GEM HEALTH's Series A round was co-led by HealthTrend Capital and LFE Capital and included participation from existing investors Base10 Partners and Mairs & Power Venture Capital. Better AI + Correct Provider Guidance = Fewer Denials  How do we tip the scale to lower the rate of denials? While AI has been the initial decision-maker for years, it must become better trained. And to do that, it needs help. Keys to Provider Patient Communications Amidst President Trump's Massive Policy Shifts  Exactly what the administration is ultimately able to accomplish will be anyone's guess, but here are some key policy and market shifts healthcare leaders and their PR teams should watch closely and be prepared to communicate around.

Video   Radical Transparency Delivered? Robert F. Kennedy Jr. is getting rid of the public comment period for certain types of HHS rulemaking. Considering he is a proponent of radical transparency, how is this going over?

Resources

MedCity Pivot Podcast: Being Clear About Cybersecurity A conversation with David Bardan, the general manager of the healthcare business at Clear, shows how the company is bringing its expertise to counter cybersecurity threats in the healthcare industry. Listen now

MedCity News • PO Box 901 • New York, NY unsubscribe